Pivotal bioVenture Partners Fund I, L.P. - 31 Dec 2025 SCHEDULE 13G Report for Evommune, Inc. Common Stock, par value $0.0001 per share (EVMN)

Filing Manager
Pivotal bioVenture Partners Fund I, L.P.
Reporting Manager
Nan Fung Group Holdings Limited
Security
Evommune, Inc. Common Stock, par value $0.0001 per share
Symbol
EVMN
Shares outstanding
31,519,257 shares
Disclosed Ownership
3,435,599 shares
Ownership
11%
Form type
SCHEDULE 13G
Filing time
13 Feb 2026, 16:10:03 UTC
Date of event
31 Dec 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Pivotal bioVenture Partners Fund I, L.P. disclosed 11% ownership in Evommune, Inc. Common Stock, par value $0.0001 per share (EVMN) on 31 Dec 2025."

Quick Takeaways

  • Pivotal bioVenture Partners Fund I, L.P. filed SCHEDULE 13G for Evommune, Inc. Common Stock, par value $0.0001 per share (EVMN).
  • Disclosed ownership: 11%.
  • Date of event: 31 Dec 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 13 Feb 2026, 16:10.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (13)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Nan Fung Group Holdings Limited 11% 3,435,599 0 3,435,599 /s/ Tang Chun Wai Nelson Tang Chun Wai Nelson, Director
NF Investment Holdings Limited 11% 3,367,975 0 3,367,975 /s/ Tang Chun Wai Nelson Tang Chun Wai Nelson, Director
Nan Fung Life Sciences Holdings Limited 11% 3,367,975 0 3,367,975 /s/ Sun Xintong Sun Xintong, Director
NFLS Platform Holdings Limited 4.6% 1,441,032 0 1,441,032 /s/ Sun Xintong Sun Xintong, Director
NFLS Delta III Limited 4.6% 1,441,032 0 1,441,032 /s/ Sun Xintong Sun Xintong, Director
Pivotal Life Sciences Holdings Limited 6.1% 1,926,943 0 1,926,943 /s/ Sun Xintong Sun Xintong, Director
Pivotal Partners Ltd 6.1% 1,926,943 0 1,926,943 /s/ Sun Xintong Sun Xintong, Director
Pivotal bioVenture Partners Fund I U.G.P. Ltd. 5.2% 1,632,441 0 1,632,441 /s/ Robert Hopfner Robert Hopfner, Authorized Signatory
Pivotal bioVenture Partners Fund I G.P., L.P. 5.2% 1,632,441 0 1,632,441 /s/ Robert Hopfner By: Pivotal bioVenture Partners Fund I U.G.P. Ltd., its general partner; By: Robert Hopfner, Authorized Signatory
Pivotal bioVenture Partners Fund I, L.P. 5.2% 1,632,441 0 1,632,441 Pivotal bioVenture Partners Fund I G.P., L.P. its general partner
Pivotal bioVenture Partners Fund II G.P. Ltd 0.9% 294,502 0 294,502 /s/ Peter Tuxen Bisgaard By: Peter Tuxen Bisgaard, Director
Pivotal bioVenture Partners Fund II, L.P. 0.9% 294,502 0 294,502 Pivotal bioVenture Partners Fund II G.P. Ltd its general partner
NFLS Delta Limited 4.6% 1,441,032 0 1,441,032 /s/ Sun Xintong Sun Xintong, Director

Sponsored